← All trials
NCT04438980
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2020
- Primary completion
- Dec 31, 2020
- Completion date
- Feb 28, 2021
- First posted
- Jun 19, 2020
- Last posted
- Jun 19, 2020
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fundacion Miguel ServetLead sponsor
- Clinica Universidad de NavarraOverall official - principal investigator
- Clinica Universidad de NavarraCollaborator
- Hospital Sant Joan Despí Moisès BroggiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.